Project description
Long non-coding RNAs as potential therapeutic targets in vascular diseases
Nucleic acid-based therapies are emerging as treatment options for many diseases. The majority of the human genome is transcribed into non-coding RNAs, including more than 15 000 long non-coding RNAs (lncRNAs). Targeting lncRNAs via RNA interference strategies provides opportunities to modulate cellular processes. The goal of the ERC-funded LongTx project is to identify lncRNAs involved in vascular disease development as potential therapeutic targets. Profiling of the diseased human tissue from patients with carotid artery disease, stroke, and abdominal aortic aneurysms led to the identification of two suitable lncRNAs. The project objectives are to study these lncRNAs in the preclinical arteries-on-chips model and in vivo in genetically modified animal models, focusing on efficient delivery of antisense oligonucleotide inhibitors to target these transcripts.
Objective
The perception that RNAs are passive carriers of genetic information has been overturned. Due to the diverse targeting abilities and extensive research in RNA modification and delivery systems, nucleic acid-based therapies have emerged as suitable treatment options for many diseases. Targeting RNAs offers opportunities to modulate numerous cellular processes, including those linked to the large portion of ‘undruggable’ proteins. Currently approved protein-targeted therapies interact with <700 gene products, meaning that only 0.05% of the human genome is presently utilized for treatment. On the contrary, a large fraction of the human genome (>70%) is transcribed into non-coding RNAs. Humans produce more than 15.000 long non-coding RNAs (lncRNA), with a substantial subset of these likely being ‘druggable’ via RNA interference strategies, such as antisense oligonucleotides and siRNAs. In my current LongTx proposal, we aim at identifying suitable lncRNAs with relevance to vascular disease development and progression. To be successful, we made sure that we have identified suitable lncRNAs by profiling diseased human tissue from patients with carotid artery disease and stroke, as well as abdominal aortic aneurysms. Both diseases are currently being treated with suboptimal surgical interventions, and the growing affected patient population would tremendously benefit from novel treatment strategies that enable stabilization of advanced vulnerable atherosclerotic lesions, and also limit the risk for acute aortic ruptures and dissections. The two lncRNAs we have identified in preliminary studies using single-cell, bulk, and spatial transcriptomics are called CRNDE and NKILA. We propose to study these lncRNAs in disease-relevant preclinical in vitro (arteries-on-chips) and in vivo (genetically mutated mice and mini-pigs) models, with a strong focus on novel local delivery concepts for antisense oligonucleotide inhibitors that site-specifically target both transcripts.
Fields of science
- medical and health sciencesclinical medicineangiologyvascular diseases
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- medical and health sciencesclinical medicinesurgerysurgical procedures
- medical and health sciencesbasic medicineneurologystroke
- natural sciencesbiological sciencesgeneticsRNA
Keywords
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Funding Scheme
HORIZON-ERC - HORIZON ERC GrantsHost institution
81675 Muenchen
Germany